Monte Rosa Therapeutics, Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 5 November 2026: press release. Guidance figures: 2 lowered, 3 new, 3 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Collaboration revenue rose on milestone: Collaboration revenue was $54.4 million, versus $12.8 million a year earlier. The company attributes the increase mainly to a $50.0 million milestone recognized in the quarter. Source
• Net income compared with prior-year loss: Net income was $3.1 million, compared with a net loss of $27.1 million a year earlier. Loss from operations narrowed to $1.9 million from $33.0 million. Source
• Cash balance fell to $582.6 million: Cash, cash equivalents, restricted cash and marketable securities were $582.6 million at September 30, down $43.4 million from $626.0 million at June 30. Source
• Runway into 2029 unchanged: Management expects cash to support operations into 2029, the same timing as the prior release. Source
• NEK7 degradation reached 80-90%: GFORCE-1 was a Phase 1 study in 108 obese subjects with elevated cardiovascular disease risk. Median NEK7 degradation was about 80% to 90% at all three dose levels. Source
• Coronary study refocused on residual inflammation: GFORCE-2 now targets stable coronary artery disease with residual inflammation. It is expected to use plaque imaging and genetics to inform a Phase 3 design. Source
• Psoriatic arthritis study started: Novartis started a second Phase 2 study of MRT-6160 in psoriatic arthritis. The $37.5 million milestone was triggered after quarter end and is not in third-quarter revenue. Source
• Prioritization pushes NEK7 IND to 2027: Management said it prioritized the MRT-8102 Phase 2 starts, so the next-generation NEK7 IND moves to 2027 from the prior H2 2026 timing. Source

“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102,”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics

Guidance

What changed from last quarter

• Guidance lowered: Next-generation NEK7 IND submission moved from H2 2026 to 2027, linked to prioritizing the MRT-8102 Phase 2 starts. Source
• Guidance lowered: GFORCE-2 Phase 2 start moved from H2 2026 to H1 2027, with the study population redefined as stable coronary artery disease with residual inflammation. Source
• New: GFORCE-1 Phase 1 results were reported in October, earlier than the prior release's H2 2026 readout expectation. Source
• New: Novartis initiated a second Phase 2 study of MRT-6160 in psoriatic arthritis, triggering a $37.5 million milestone. Source
• New: First patient dosed in the MODeFIRe-1 Phase 2 study of MRT-2359 with apalutamide, reported as occurring in August. Source

Collaboration revenue and net income

• Collaboration revenue rose on milestone: Collaboration revenue was $54.4 million, versus $12.8 million a year earlier. The company attributes the increase mainly to a $50.0 million milestone recognized in the quarter. Source
• Net income compared with prior-year loss: Net income was $3.1 million, compared with a net loss of $27.1 million a year earlier. Loss from operations narrowed to $1.9 million from $33.0 million. Source
• Nine-month net loss compared with income: Nine-month net loss was $84.8 million, against net income of $7.5 million a year earlier. Nine-month collaboration revenue was $67.5 million, down from $120.9 million. Source

Operating costs: R&D and G&A

• R&D spend rose on programs: R&D expense was $45.4 million, versus $36.7 million, including $3.3 million of non-cash stock-based compensation. The company attributed the rise to development and discovery programs. Source
• G&A expense rose to $10.9 million: G&A expense was $10.9 million, against $9.1 million a year earlier, including $3.0 million of non-cash stock-based compensation. Source
• Nine-month R&D and G&A totals: Nine-month R&D expense was $137.4 million against $99.5 million, and nine-month G&A expense was $31.3 million against $25.9 million. Source

“The GFORCE-1 results reinforce our view that targeting NEK7 at the top of the NLRP3 signaling cascade could address a broader set of disease drivers than targeting individual downstream cytokines.”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics

Cash, balance sheet and runway

• Cash balance fell to $582.6 million: Cash, cash equivalents, restricted cash and marketable securities were $582.6 million at September 30, down $43.4 million from $626.0 million at June 30. Source
• Milestone cash not yet received: The company said cash receipts from the milestones were not reflected at September 30 because payments had not been received. Collaboration receivable on the balance sheet was $50.0 million. Source
• Runway into 2029 unchanged: Management expects cash to support operations into 2029, the same timing as the prior release. Source
• Shares outstanding rose to 85.4 million: Shares issued and outstanding were 85,431,211 at September 30, 2026, versus 65,543,723 at December 31, 2025. The documents do not state the reason for the increase. Source

MRT-8102 GFORCE-1 Phase 1 results

• NEK7 degradation reached 80-90%: GFORCE-1 was a Phase 1 study in 108 obese subjects with elevated cardiovascular disease risk. Median NEK7 degradation was about 80% to 90% at all three dose levels. Source
• Inflammatory markers fell in study: Reductions were reported in IL-1β and in HMGB1, calprotectin, S100A12 and SAA, damage-associated molecular patterns tied to plaque and vessel-wall biology. Source
• Safety comparable to placebo: No serious adverse events were reported. Adverse event rates were similar to placebo, with no evidence of increased infection risk. Source

“We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use.”

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics

MRT-8102 Phase 2 study plans

• Gout study targets flare prevention: GEMINI-1 in gout will test prevention of flare recurrence after acute flares are managed. Start is expected in Q4 2026, with initial data in H2 2027. Source
• Coronary study refocused on residual inflammation: GFORCE-2 now targets stable coronary artery disease with residual inflammation. It is expected to use plaque imaging and genetics to inform a Phase 3 design. Source
• Hidradenitis study timing unchanged: GALAXY-1 in moderate to severe hidradenitis suppurativa remains expected to start in H1 2027, the same timing as the prior release. Source

VAV1 program with Novartis

• Psoriatic arthritis study started: Novartis started a second Phase 2 study of MRT-6160 in psoriatic arthritis. The $37.5 million milestone was triggered after quarter end and is not in third-quarter revenue. Source
• More VAV1 studies expected: The company said the Sjögren’s and psoriatic arthritis studies are the first two of several expected for MRT-6160. Dates for the others were not given. Source
• Milestones tied to each Phase 2 start: Monte Rosa is eligible for additional Phase 2 study initiation milestone payments under its license agreement with Novartis. Source

MRT-2359 in prostate cancer

• MODeFIRe-1 first patient dosed: MODeFIRe-1 dosed its first patient in August. The study will enroll up to 25 patients, dosed orally at 0.5 mg with apalutamide, in AR-mutant mCRPC. Source
• Enzalutamide arm enrollment complete: Six patients with AR mutations were enrolled and treated in the initial Phase 1/2 expansion arm combining MRT-2359 with enzalutamide. An update on that subset is planned by year-end. Source
• GSPT1 and MYC rationale restated: Management said prior work showed GSPT1 degradation dampens MYC signaling in CRPC, a pathway it believes is moving to center stage. Source

CDK2 and CCNE1 programs

• Two IND filings planned for 2027: Management expects IND applications for its CDK2 and CCNE1 MGD programs in 2027. Source
• CCNE1 timing matches prior release: The CCNE1 IND timing of 2027 is the same as in the prior release. Source
• CDK2 indication no longer named: The prior release described the CDK2 program as advancing toward clinical development for ER+ breast cancer. The current release names no indication for CDK2. Source

Timing and development priorities

• GFORCE-1 results reported in October: The prior release expected the GFORCE-1 readout in H2 2026. The company reported positive results in October, within that window. Source
• Prioritization pushes NEK7 IND to 2027: Management said it prioritized the MRT-8102 Phase 2 starts, so the next-generation NEK7 IND moves to 2027 from the prior H2 2026 timing. Source
• Novartis 2026 start expectation undated: The prior release expected Novartis to start multiple VAV1 Phase 2 studies in 2026. The current release gives no date for the further studies. Source

Coming up, as management said on 5 November 2026

• Gout Phase 2 start in Q4 2026: GEMINI-1 gout study is expected to start in Q4 2026, with initial data in H2 2027. Source
• Coronary study start in H1 2027: GFORCE-2 Phase 2b study in stable coronary artery disease is expected to start in H1 2027. Source
• Hidradenitis study start in H1 2027: GALAXY-1 Phase 2 study in hidradenitis suppurativa is expected to start in H1 2027. Source
• MRT-2359 data updates ahead: An enzalutamide arm update is due by year-end 2026, and a MODeFIRe-1 data update is expected in 2027. Source
• CDK2 and CCNE1 IND filings in 2027: IND applications for the CDK2 and CCNE1 MGD programs are expected in 2027. Source
• More Novartis VAV1 Phase 2 starts: Several further Phase 2 studies of MRT-6160 are expected under the Novartis collaboration. Source

Figures management reported

Risks management discussed

• Operational: Prioritizing the MRT-8102 Phase 2 starts moves the next-generation NEK7 IND submission into 2027. Source

Earlier plans management reported on

• Not stated: The prior release expected the readout in H2 2026. The current release reports the results as reported in October.
• Not stated: The prior release targeted first dosing in Q3 2026. The current release reports the first patient dosed in August.
• Not stated: Management plans an update on the AR-mutant subset of the enzalutamide arm by the end of the year. Source
• Not stated: The prior release expected Novartis to start multiple immune-disease Phase 2 studies in 2026. The current release gives no date for the further studies.
• Not stated: The prior release expected the IND submission in H2 2026. The current release anticipates it in 2027.

Other quarters

• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q3 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.